BRPI0511328A - cis-imidazolinas - Google Patents
cis-imidazolinasInfo
- Publication number
- BRPI0511328A BRPI0511328A BRPI0511328-8A BRPI0511328A BRPI0511328A BR PI0511328 A BRPI0511328 A BR PI0511328A BR PI0511328 A BRPI0511328 A BR PI0511328A BR PI0511328 A BRPI0511328 A BR PI0511328A
- Authority
- BR
- Brazil
- Prior art keywords
- cis
- imidazolines
- imidazolins
- peptide
- inhibit
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/06—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/22—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D233/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings
- C07D233/04—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
- C07D233/20—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with substituted hydrocarbon radicals, directly attached to ring carbon atoms
- C07D233/26—Radicals substituted by carbon atoms having three bonds to hetero atoms
Abstract
CIS-IMIDAZOLINAS e seus sais e ésteres farmaceuticamente aceitáveis, onde X~ 1~, X~ 2~, X~ 3~,Y~ 1~, Y~ 2~ e R são descritos, aqui inibem a interação da proteína MDM2 com um peptídeo do tipo p53 e então têm atividade antiproliferativa.
Applications Claiming Priority (4)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US57227504P | 2004-05-18 | 2004-05-18 | |
US61553404P | 2004-10-01 | 2004-10-01 | |
US66877205P | 2005-04-06 | 2005-04-06 | |
PCT/EP2005/005046 WO2005110996A1 (en) | 2004-05-18 | 2005-05-10 | Novel cis-imidazolines |
Publications (1)
Publication Number | Publication Date |
---|---|
BRPI0511328A true BRPI0511328A (pt) | 2007-12-04 |
Family
ID=35058746
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
BRPI0511328-8A BRPI0511328A (pt) | 2004-05-18 | 2005-05-10 | cis-imidazolinas |
Country Status (21)
Country | Link |
---|---|
US (2) | US7964724B2 (pt) |
EP (1) | EP1753727B1 (pt) |
JP (1) | JP4814228B2 (pt) |
KR (3) | KR100832277B1 (pt) |
CN (1) | CN1953965B (pt) |
AR (1) | AR049545A1 (pt) |
AT (1) | ATE414693T1 (pt) |
AU (1) | AU2005243465B2 (pt) |
BR (1) | BRPI0511328A (pt) |
CA (1) | CA2565189A1 (pt) |
DE (1) | DE602005011132D1 (pt) |
ES (1) | ES2314660T3 (pt) |
IL (1) | IL178884A (pt) |
MX (1) | MXPA06013246A (pt) |
MY (1) | MY143800A (pt) |
NO (1) | NO20065730L (pt) |
PE (1) | PE20060679A1 (pt) |
RU (1) | RU2006144811A (pt) |
TW (1) | TW200600501A (pt) |
WO (1) | WO2005110996A1 (pt) |
ZA (1) | ZA200609595B (pt) |
Families Citing this family (66)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US7893278B2 (en) * | 2004-06-17 | 2011-02-22 | Hoffman-La Roche Inc. | CIS-imidazolines |
KR101139263B1 (ko) * | 2005-03-16 | 2012-05-16 | 에프. 호프만-라 로슈 아게 | 시스-2,4,5-트리아릴-이미다졸린 및 항암 약제로서의그의 용도 |
JP4870778B2 (ja) | 2005-12-01 | 2012-02-08 | エフ.ホフマン−ラ ロシュ アーゲー | 抗ガン剤として使用されるp53およびmdm2タンパク質間の相互作用の阻害剤としての2,4,5−トリフェニルイミダゾリン誘導体 |
JP2009523751A (ja) * | 2006-01-18 | 2009-06-25 | エフ.ホフマン−ラ ロシュ アーゲー | Mdm2阻害剤としてのシス−4,5−ビアリール−2−ヘテロサイクリック−イミダゾリン |
US7884107B2 (en) | 2006-06-30 | 2011-02-08 | Merck | Substituted piperidines that increase P53 activity and the uses thereof |
AU2007327621A1 (en) * | 2006-11-27 | 2008-06-05 | Novartis Ag | Substituted dihydroimidazoles and their use in the treatment of tumors |
WO2008072655A1 (ja) | 2006-12-14 | 2008-06-19 | Daiichi Sankyo Company, Limited | イミダゾチアゾール誘導体 |
PT2118123E (pt) * | 2007-01-31 | 2016-02-10 | Harvard College | Péptidos de p53 estabilizados e suas utilizações |
EP2508531B1 (en) | 2007-03-28 | 2016-10-19 | President and Fellows of Harvard College | Stitched polypeptides |
US7625895B2 (en) * | 2007-04-12 | 2009-12-01 | Hoffmann-Le Roche Inc. | Diphenyl-dihydro-imidazopyridinones |
AU2008309759A1 (en) | 2007-10-09 | 2009-04-16 | F. Hoffmann-La Roche Ag | Chiral CIS-imidazolines |
JPWO2009151069A1 (ja) | 2008-06-12 | 2011-11-17 | 第一三共株式会社 | 4,7−ジアザスピロ[2.5]オクタン環構造を有するイミダゾチアゾール誘導体 |
DE102008047128A1 (de) | 2008-09-15 | 2010-04-15 | Johann Wolfgang Goethe-Universität Frankfurt am Main | Verwendung von cis-Imidazolinen, insbesondere Nutlinen, zur Behandlung von chemoresistenten Krebserkrankungen |
KR20110119641A (ko) | 2009-01-16 | 2011-11-02 | 다이이찌 산쿄 가부시키가이샤 | 프롤린 고리 구조를 갖는 이미다조티아졸 유도체 |
UA109417C2 (uk) | 2009-10-14 | 2015-08-25 | Мерк Шарп Енд Доме Корп. | ЗАМІЩЕНІ ПІПЕРИДИНИ, ЯКІ ПІДВИЩУЮТЬ АКТИВНІСТЬ p53, І ЇХ ЗАСТОСУВАННЯ |
UA107814C2 (uk) | 2009-11-12 | 2015-02-25 | Дзе Ріджентс Оф Дзе Юніверсіті Оф Мічіган | Спірооксіндольні антагоністи мdм2 |
US8440693B2 (en) | 2009-12-22 | 2013-05-14 | Novartis Ag | Substituted isoquinolinones and quinazolinones |
WO2011106650A2 (en) * | 2010-02-27 | 2011-09-01 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Novel p53-mdm2/p53-mdm4 antagonists to treat proliferative disease |
JO2998B1 (ar) | 2010-06-04 | 2016-09-05 | Amgen Inc | مشتقات بيبيريدينون كمثبطات mdm2 لعلاج السرطان |
CA2807685C (en) | 2010-08-13 | 2020-10-06 | Aileron Therapeutics, Inc. | P53 derived peptidomimetic macrocycle |
CA2813256A1 (en) | 2010-09-30 | 2012-04-05 | St. Jude Children's Research Hospital | Aryl-substituted imidazoles |
WO2012065022A2 (en) | 2010-11-12 | 2012-05-18 | The Regents Of The University Of Michigan | Spiro-oxindole mdm2 antagonists |
RU2612534C2 (ru) | 2011-03-10 | 2017-03-09 | Дайити Санкио Компани, Лимитед | Диспиропирролидиновые производные |
AU2012253339B2 (en) | 2011-05-11 | 2016-03-31 | Sanofi | Spiro-oxindole MDM2 antagonists |
MX352672B (es) | 2011-09-27 | 2017-12-04 | Amgen Inc | Compuestos heterocíclicos como inhibidores de mdm2 para el tratamiento del cáncer. |
WO2013054153A1 (en) | 2011-10-11 | 2013-04-18 | INSERM (Institut National de la Santé et de la Recherche Médicale) | Nutlin compounds for use in he treatment of pulmonary hypertension |
TWI643868B (zh) | 2011-10-18 | 2018-12-11 | 艾利倫治療公司 | 擬肽巨環化合物 |
WO2013062923A1 (en) | 2011-10-28 | 2013-05-02 | Merck Sharp & Dohme Corp. | MACROCYCLES THAT INCREASE p53 ACTIVITY AND THE USES THEREOF |
US8969341B2 (en) | 2011-11-29 | 2015-03-03 | Novartis Ag | Pyrazolopyrrolidine compounds |
EP2793890B1 (en) | 2011-12-21 | 2016-09-07 | Merck Sharp & Dohme Corp. | Substituted piperidines as hdm2 inhibitors |
UY34591A (es) | 2012-01-26 | 2013-09-02 | Novartis Ag | Compuestos de imidazopirrolidinona |
MX362492B (es) | 2012-02-15 | 2019-01-21 | Aileron Therapeutics Inc | Macrociclos peptidomiméticos. |
US8987414B2 (en) | 2012-02-15 | 2015-03-24 | Aileron Therapeutics, Inc. | Triazole-crosslinked and thioether-crosslinked peptidomimetic macrocycles |
US9365576B2 (en) | 2012-05-24 | 2016-06-14 | Novartis Ag | Pyrrolopyrrolidinone compounds |
TWI586668B (zh) | 2012-09-06 | 2017-06-11 | 第一三共股份有限公司 | 二螺吡咯啶衍生物之結晶 |
EP2914256B1 (en) | 2012-11-01 | 2019-07-31 | Aileron Therapeutics, Inc. | Disubstituted amino acids and methods of preparation and use thereof |
WO2014100065A1 (en) | 2012-12-20 | 2014-06-26 | Merck Sharp & Dohme Corp. | Substituted imidazopyridines as hdm2 inhibitors |
WO2014115080A1 (en) | 2013-01-22 | 2014-07-31 | Novartis Ag | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the p53/mdm2 interaction |
EP2948451B1 (en) | 2013-01-22 | 2017-07-12 | Novartis AG | Substituted purinone compounds |
US9540377B2 (en) | 2013-01-30 | 2017-01-10 | Merck Sharp & Dohme Corp. | 2,6,7,8 substituted purines as HDM2 inhibitors |
US11407721B2 (en) | 2013-02-19 | 2022-08-09 | Amgen Inc. | CIS-morpholinone and other compounds as MDM2 inhibitors for the treatment of cancer |
AU2014223547B2 (en) | 2013-02-28 | 2017-11-16 | Amgen Inc. | A benzoic acid derivative MDM2 inhibitor for the treatment of cancer |
MX2015012427A (es) | 2013-03-14 | 2016-01-12 | Amgen Inc | Compuestos de morfolinona de acido heteroarilo como inhibidores mdm2 para el tratamiento de cancer. |
WO2014165816A1 (en) | 2013-04-05 | 2014-10-09 | North Carolina Central University | Compounds useful for the treatment of metabolic disorders and synthesis of the same |
EP3004109A1 (en) | 2013-05-27 | 2016-04-13 | Novartis AG | Imidazopyrrolidinone derivatives and their use in the treatment of disease |
US8975417B2 (en) | 2013-05-27 | 2015-03-10 | Novartis Ag | Pyrazolopyrrolidine derivatives and their use in the treatment of disease |
PL3004112T3 (pl) | 2013-05-28 | 2018-02-28 | Novartis Ag | Pochodne pirazolo-pirolidyn-4-onu oraz ich zastosowanie w leczeniu choroby |
ES2656471T3 (es) | 2013-05-28 | 2018-02-27 | Novartis Ag | Derivados de pirazolo-pirrolidin-4-ona como inhibidores de BET y su uso en el tratamiento de enfermedades |
CN104208066B (zh) * | 2013-06-03 | 2016-06-15 | 中国科学院遗传与发育生物学研究所 | 哌嗪衍生物作为p53分子调节剂的用途 |
JOP20200296A1 (ar) | 2013-06-10 | 2017-06-16 | Amgen Inc | عمليات صنع وأشكال بلورية من mdm2 مثبط |
US9550796B2 (en) | 2013-11-21 | 2017-01-24 | Novartis Ag | Pyrrolopyrrolone derivatives and their use as BET inhibitors |
CN107106642B (zh) | 2014-09-24 | 2021-02-26 | 艾瑞朗医疗公司 | 拟肽大环化合物及其制剂 |
SG10201902594QA (en) | 2014-09-24 | 2019-04-29 | Aileron Therapeutics Inc | Peptidomimetic macrocycles and uses thereof |
ES2738630T3 (es) | 2015-01-22 | 2020-01-24 | Sanofi Aventis Deutschland | Procedimiento para la producción de 2-[4-(ciclopropanocarbonil)fenil]-2-metil-propanonitrilo |
AU2016235424A1 (en) | 2015-03-20 | 2017-10-05 | Aileron Therapeutics, Inc. | Peptidomimetic macrocycles and uses thereof |
EP3347372A4 (en) | 2015-09-10 | 2019-09-04 | Aileron Therapeutics, Inc. | PEPTIDOMIMETIC MACROCYCLES AS MODULATORS OF MCL-1 |
RU2021102253A (ru) | 2016-04-06 | 2021-03-03 | Дзе Риджентс Оф Дзе Юниверсити Оф Мичиган | Деструкторы белка mdm2 |
JP7001614B2 (ja) | 2016-04-06 | 2022-02-03 | ザ リージェンツ オブ ザ ユニヴァシティ オブ ミシガン | リガンド依存性の標的タンパク質分解のための単官能性中間体 |
JP2019522633A (ja) | 2016-05-20 | 2019-08-15 | ジェネンテック, インコーポレイテッド | Protac抗体コンジュゲート及び使用方法 |
WO2019079677A1 (en) * | 2017-10-20 | 2019-04-25 | Corbus Pharmaceuticals, Inc. | METHODS AND COMPOSITIONS RELATING TO 5- (1,1-DIMETHYLHEPTYL) -ORRESORCINOL ULTRAPUR |
US11046703B2 (en) | 2018-10-08 | 2021-06-29 | The Regents Of The University Of Michigan | Small molecule MDM2 protein degraders |
WO2021188948A1 (en) | 2020-03-19 | 2021-09-23 | Kymera Therapeutics, Inc. | Mdm2 degraders and uses thereof |
WO2023056069A1 (en) | 2021-09-30 | 2023-04-06 | Angiex, Inc. | Degrader-antibody conjugates and methods of using same |
US11548866B1 (en) | 2021-11-22 | 2023-01-10 | Ligature Therapeutics Pte. Ltd. | Therapeutic compounds and methods of use thereof |
US11504381B1 (en) * | 2021-11-22 | 2022-11-22 | Ligature Therapeutics Pte. Ltd. | Therapeutic compounds and methods of use thereof |
KR20230087856A (ko) | 2021-12-10 | 2023-06-19 | 교촌 에프 앤 비(주) | 생체이용율과 이미다졸 펩타이드가 증가된 수용성 닭가슴살 가수분해물 및 그 제조방법 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
JPH02101065A (ja) | 1988-10-06 | 1990-04-12 | Tanabe Seiyaku Co Ltd | イミダゾリン誘導体及びその製法 |
DE4203547A1 (de) * | 1992-02-07 | 1993-08-12 | Knoll Ag | Verfahren zur racemattrennung von verapamil |
FR2756560A1 (fr) * | 1996-12-04 | 1998-06-05 | Adir | Nouveaux derives de l'imidazoline, leur procede de preparation et les compositions pharmaceutiques qui les contiennent |
GB2351082A (en) | 1999-06-18 | 2000-12-20 | Lilly Forschung Gmbh | Synthesis of Cyclic Substituted Amidines |
US6653501B2 (en) * | 2001-06-27 | 2003-11-25 | Napro Biotherapeutics, Inc. | Chiral resolution method for producing compounds useful in the synthesis of taxanes |
ES2301717T3 (es) * | 2001-12-18 | 2008-07-01 | F. Hoffmann-La Roche Ag | Cis-2,4,5-trifenil-imidazolinas y su utilizacion para el tratamiento de tumores. |
MXPA04005880A (es) * | 2001-12-18 | 2004-09-13 | Hoffmann La Roche | Cis-imidazolinas como inhibidores de la mdm2. |
-
2005
- 2005-05-10 BR BRPI0511328-8A patent/BRPI0511328A/pt not_active IP Right Cessation
- 2005-05-10 CN CN200580015663XA patent/CN1953965B/zh not_active Expired - Fee Related
- 2005-05-10 WO PCT/EP2005/005046 patent/WO2005110996A1/en active Application Filing
- 2005-05-10 RU RU2006144811/04A patent/RU2006144811A/ru not_active Application Discontinuation
- 2005-05-10 ES ES05742255T patent/ES2314660T3/es active Active
- 2005-05-10 CA CA002565189A patent/CA2565189A1/en not_active Abandoned
- 2005-05-10 EP EP05742255A patent/EP1753727B1/en active Active
- 2005-05-10 KR KR1020067024089A patent/KR100832277B1/ko not_active IP Right Cessation
- 2005-05-10 KR KR1020087005155A patent/KR20080027969A/ko not_active Application Discontinuation
- 2005-05-10 AU AU2005243465A patent/AU2005243465B2/en not_active Ceased
- 2005-05-10 DE DE602005011132T patent/DE602005011132D1/de active Active
- 2005-05-10 MX MXPA06013246A patent/MXPA06013246A/es active IP Right Grant
- 2005-05-10 JP JP2007517027A patent/JP4814228B2/ja not_active Expired - Fee Related
- 2005-05-10 KR KR1020117006619A patent/KR20110033964A/ko not_active IP Right Cessation
- 2005-05-10 AT AT05742255T patent/ATE414693T1/de active
- 2005-05-13 US US11/129,621 patent/US7964724B2/en not_active Expired - Fee Related
- 2005-05-16 PE PE2005000539A patent/PE20060679A1/es not_active Application Discontinuation
- 2005-05-16 TW TW094115741A patent/TW200600501A/zh unknown
- 2005-05-16 AR ARP050101998A patent/AR049545A1/es not_active Application Discontinuation
- 2005-05-16 MY MYPI20052212A patent/MY143800A/en unknown
-
2006
- 2006-10-26 IL IL178884A patent/IL178884A/en not_active IP Right Cessation
- 2006-11-17 ZA ZA200609595A patent/ZA200609595B/xx unknown
- 2006-12-12 NO NO20065730A patent/NO20065730L/no not_active Application Discontinuation
-
2009
- 2009-02-05 US US12/366,381 patent/US20090143364A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
KR20080027969A (ko) | 2008-03-28 |
RU2006144811A (ru) | 2008-06-27 |
PE20060679A1 (es) | 2006-08-11 |
MY143800A (en) | 2011-07-15 |
CN1953965B (zh) | 2012-07-04 |
AR049545A1 (es) | 2006-08-16 |
DE602005011132D1 (de) | 2009-01-02 |
US20090143364A1 (en) | 2009-06-04 |
TW200600501A (en) | 2006-01-01 |
IL178884A0 (en) | 2007-03-08 |
IL178884A (en) | 2010-12-30 |
AU2005243465A1 (en) | 2005-11-24 |
MXPA06013246A (es) | 2007-02-08 |
KR100832277B1 (ko) | 2008-05-26 |
ATE414693T1 (de) | 2008-12-15 |
ES2314660T3 (es) | 2009-03-16 |
AU2005243465B2 (en) | 2011-08-25 |
US20050288287A1 (en) | 2005-12-29 |
WO2005110996A1 (en) | 2005-11-24 |
CA2565189A1 (en) | 2005-11-24 |
ZA200609595B (en) | 2008-06-25 |
JP4814228B2 (ja) | 2011-11-16 |
JP2007538022A (ja) | 2007-12-27 |
EP1753727B1 (en) | 2008-11-19 |
US7964724B2 (en) | 2011-06-21 |
EP1753727A1 (en) | 2007-02-21 |
CN1953965A (zh) | 2007-04-25 |
NO20065730L (no) | 2007-01-19 |
KR20070011516A (ko) | 2007-01-24 |
KR20110033964A (ko) | 2011-04-01 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
BRPI0511328A (pt) | cis-imidazolinas | |
CY1119243T1 (el) | Φαρμακοτεχνικες μορφες ανταγωνιστη του vegf | |
PE20030895A1 (es) | Cis-imidazolinas | |
NO2017028I2 (no) | eftrenonacog alfa eller et biotilsvarende legemiddel ihht Artikkel 10(4) av Directive 2001/83/EC, som beskyttet av basispatentet. | |
BR0215156A (pt) | Cis-imidazolinas como inibidores de mdm 2 | |
CY1113537T1 (el) | Οξινα σκευασματα ινσουλινης με βελτιωμενη σταθεροτητα | |
BR0205890A (pt) | Pirazolopirimidinas como agentes terapêuticos | |
CY1111825T1 (el) | Φαρμακευτικες συνθεσεις οι οποιες περιλαμβανουν ενα οπιουχο ανταγωνιστη | |
DE60319848D1 (de) | Medikament mit mesenchym-stammzellen | |
CR20110221A (es) | Terapia de combinación con péptidos epoxicetonas peptídicas | |
NO2011025I1 (no) | Telavancin, eller et farmasøytisk aksseptabelt salt derav, herunder inkludert telavancin hydroklorid | |
BRPI0408782A (pt) | inibidores cìclicos da proteìna tirosina cinase | |
NO20073244L (no) | Konjugeringsprodukt | |
NO20044039L (no) | Konjugatorer av terapeutiske eller cytotoksiske midler og biologisk aktive peptider. | |
BRPI0513477A (pt) | composições e processos de uso de proteìna 4 semelhante a angiotensina | |
NO20063393L (no) | Farmasoytiske preparater | |
BRPI0508485A (pt) | compostos de pentafluorsulfanila, sua fabricação e uso como agentes farmacêuticos | |
ITMI20021726A1 (it) | Macrolidi ad attivita' antiinfiammatoria. | |
ITMI20022292A1 (it) | 9a-azalidi ad attivita' antiinfiammatoria. | |
TW200510387A (en) | Cis-2, 4, 5-triaryl-imidazolines | |
ATE404602T1 (de) | Wässrige polyurethanzubereitungen | |
BRPI0411597A (pt) | cis-imidazolinas como inibidores de mdm2 | |
ATE458747T1 (de) | Angiontensin converting enzyme hemmendes peptid | |
ATE474589T1 (de) | Angiogene peptide und ihre verwendungen | |
ATE360644T1 (de) | Vegf-peptide und deren verwendung |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
B08F | Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette] |
Free format text: REFERENTE A 9A ANUIDADE. |
|
B08K | Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette] |
Free format text: REFERENTE AO DESPACHO 8.6 PUBLICADO NA RPI 2257 DE 08/04/2014. |